Recap: Catalyst Pharmaceuticals Q3 Earnings
Portfolio Pulse from Benzinga Insights
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported its Q3 earnings results, beating estimated earnings by 11.36% with an EPS of $0.49 versus an estimate of $0.44. Revenue was up $45.44 million from the same period last year. Last quarter, the company beat on EPS by $0.11, which was followed by a 6.37% increase in the share price the next day.
November 08, 2023 | 9:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Catalyst Pharmaceuticals reported strong Q3 earnings, beating estimates by 11.36%. This follows a trend from last quarter where a beat on EPS led to a 6.37% increase in share price.
Catalyst Pharmaceuticals has reported strong Q3 earnings, beating estimates by a significant margin. This is likely to be viewed positively by the market, especially considering the company's past performance where a beat on EPS led to a substantial increase in share price. Therefore, it is expected that this news will have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100